• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

Hypertrophic Cardiomyopathy HCM is the most common genetic disorder of the heart, with 1
case per 200 to 500 persons, and often remains clinically silent. HCM is the most common …

Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by left
ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle …

The present document has been conceived as the European update to the American
College of Cardiology (ACC)/American Heart Association (AHA)/ESC 2006 Guidelines for …

Kardiomiopatie definiuje się jako strukturalne oraz funkcjonalne nieprawidłowości mięśnia
komór, które nie wynikają z niedokrwienia na skutek choroby wieńcowej czy …

Background—Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden
death in the young, although not all patients eligible for sudden death prevention with an …

Importance Strategies for reliable selection of high-risk patients with hypertrophic
cardiomyopathy (HCM) for prevention of sudden cardiac death (SCD) with implantable …

Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with diverse
phenotypic and genetic expression, clinical presentation, and natural history. HCM has been …